| Cat. No. |
Product Name |
Information |
| PC-28071 |
QTX3034
KRAS inhibitor
|
QTX3034 is a potent, highly selective, orally bioavailable allosteric multi-KRAS inhibitor that is efficacious against a broad spectrum of the more common KRASG12D-and KRASG12V-mutated cancers in vitro and in vivo. |
| PC-28064 |
Salirasib
Ras inhibitor
|
Salirasib (S-Farnesylthiosalicylic acid, FTS) is an oral RAS inhibitor, shows potent competitive inhibitor of prenylated protein methyltransferase (PPMTase) with Ki of 2.6 uM, inhibits the active forms of Ras proteins. |
| PC-27646 |
AM-8719
KRAS G12C inhibitor
|
AM-8719 (AM8719) is a potent, selective, CNS-penetrant, orally efficacious KRAS G12C inhibitor with cellular activity (p-ERK, IC50=157 nM). |
| PC-27628 |
KRAS-Q61X inhibitor compound 2
KRAS-Q61X inhibitor
|
KRAS-Q61X inhibitor compound 2 is a specific small molecule ligand of KRAS-Q61X (X = H, L, K, R), selectively activates GTP hydrolysis of KRAS-Q61X, suppresses KRAS-Q61X signaling. |
| PC-27627 |
KRAS-Q61X inhibitor compound 1
KRAS-Q61X inhibitor
|
KRAS-Q61X inhibitor compound 1 is a specific small molecule ligand of KRAS-Q61X (X = H, L, K, R), selectively activates GTP hydrolysis of KRAS-Q61X mutants. |
| PC-27514 |
Zecdarasib
KRAS G12D inhibitor
|
Zecdarasib (INCB161734, INCB-161734) is a potent, selective KRAS G12D inhibitor. |
| PC-27075 |
RMC-8839
KRAS G13C inhibitor
|
RMC-8839 (RMC8839) is a potent, selective, covalent and orally active RAS(ON) G13C tri-complex inhibitor with biochemical Kinact of 2.83 x 10-3 s-1 and Ki of 28.3 nM. |
| PC-26762 |
RMC-5127
RAS(ON) G12V inhibitor
|
RMC-5127 (RMC5127) is a potent, selective and orally bioavailable RAS(ON) G12V inhibitor with EC50 of 2.1 nM, 26-fold selective over RAS WT. |
| PC-26456 |
DJX-A-KM
KRASG12C degrader
|
DJX-A-KM is a potent, selective FBXO28-recruiting degrader of KRASG12C with DC50 of 2 nM in NCI-H23 cells, Dmax=98%. |
| PC-26265 |
IACS-56676
NRAS G12D inhibitor
|
IACS-56676 is a selective and potent NRAS G12D inhibitor with target engagement IC50 of 31 nM in AlphaLISA p-ERK1/2 assays, and IC50 of 73 nM in THP1 cell viability assay, displays >100-fold selectivity for NRAS G12D over KRAS wild type. |
| PC-26225 |
BBO-11818
KRAS inhibitor
|
BBO-11818 is a potent, selective, orally bioavailable noncovalent pan-KRAS inhibitor, potently disrupts the interaction of RAF1-RAS Binding Domain (RBD) with KRASG12D (IC50=28 nM), KRASG12V (IC50=61 nM), KRASG12C (IC50=47 nM), and KRASG12R (IC50=51 nM), as well as KRASWT (IC50=120 nM). |
| PC-26023 |
Dual SLC25A51 and SDHA inhibitor 615
SLC25A51/SDHA inhibitor
|
Dual SLC25A51 and SDHA inhibitor 615 (Compound 615, 666-15) is a specific small molecule dual inhibitor of SLC25A51 and succinate dehydrogenase (SDH) subunit SDHA, selectively kills KRAS-mutated cells. |
